with H2E-tumors who were obese (BMI>30kg/m2) had a 2.12-fold (95%CI=1.12-4.04) higher risk of recurrence and 2-fold (95%CI=1.19-3.641) higher risk of mortality than women with BMI<25kg/m2. BMI was not associated with risks of recurrence or mortality among patients with luminal A or luminal B tumors. Previous studies indicate that obese breast cancer survivors have worse outcomes. However, our results suggest that obesity is associated with increased risks of recurrence and mortality only among younger women with H2E disease. The mechanism underlying these relationships is unclear, but if confirmed, these associations suggest that weight-loss interventions may be particularly beneficial for premenopausal H2E breast cancer patients.
INTRODUCTION
Breast cancer is a heterogeneous disease consisting of distinct molecular subtypes defined by patterns of gene expression or joint tumor marker expression with unique biologic features. Protein expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) is routinely used to classify tumors as: luminal A (ER+ or PR+/HER2-), luminal B (ER+ or PR+/HER2+), HER2-overexpressing (H2E) (ER-/HER2+), and triple negative (TN) (ER-/PR-/HER-2) 1, 2 . These different subtypes are clinically meaningful and exhibit distinct clinical profiles, responses to therapy, and oncologic outcomes. While luminal subtypes (ER+) appear to have better prognosis, H2E
and TN tumors are associated with worse recurrence rates and survival 3, 4 .
Though the clinical differences across molecular subtypes have been well-studied, factors influencing recurrence and survival differences are less thoroughly understood. Obesity is an established risk factor for the development of postmenopausal breast cancer 5, 6 and has been linked to poor prognosis 7 . Prior studies suggest that the relationship between BMI and breast cancer risk differs by molecular subtype. For instance, obesity has been linked to an increased risk of ER+ cancers among postmenopausal women 8 . In premenopausal women, obesity may be associated with a decreased risk of ER+ breast cancers, 8, 9 but contribute to a higher incidence of TN cancers. [9] [10] [11] The literature also points to a greater risk of breast-cancer recurrence and mortality with obesity 7, 12, 13 . Biological differences and the known heterogeneous relationship between obesity and incidence lead us to hypothesize that obesity may have divergent impacts on prognosis among breast cancer subtypes. However, research on recurrence and survival has largely focused on all breast cancer subtypes as one group, limiting our ability to assess the prognostic effect of obesity in specific breast cancer subtypes.
The known differences between molecular subtypes of breast cancer lend biological plausibility to the hypothesis that tumors differing in ER status may respond differently to obesity, contributing to established differences in recurrence and survival. 
METHODS

Study design and population
We conducted a population-based prospective cohort study of women aged 20-69 years In New Mexico, the medical records of all 681 eligible breast cancer cases (response rate: 100%)
were reviewed under an IRB approved waiver of consent. In Seattle, 2,882 of 4,508 (response rate: 64%) eligible women newly diagnosed with invasive breast cancer during the study period were enrolled in addition to 994 eligible participants identified from prior studies with overlapping eligibility criteria (the design and methods of these studies have been previously described 15, 16 ). Seattle participants were further approached for their consent to participate in a structured interview covering a variety of topics related to breast cancer risk factors. Among 3,876 enrolled participants, interview and medical records data were both obtained for 2,965, medical record only data were available for 536 and interview only data were available for 375 women. To overcome the potential bias that would have resulted from only including participants who were alive at enrollment, eligible deceased women were enrolled at both study sites through a waiver of consent. Data on deceased women were obtained only through the review of medical records. For this analysis, we excluded 40 women for which BMI data was not available. Our final cohort included a total of 4,517 women with breast cancer, 2,036 luminal A, 333
luminal B, 1,539 TN, and 609 H2E cases.
Data collection
Data on demographic and clinical factors were collected via medical record abstraction for participants at the New Mexico site and via both medical record review and structured telephone interview for participants in Seattle. For all variables, the primary source of data was medical records.
Interview data were used to supplement data missing from medical records.
Body mass index (BMI) at the time of diagnosis was the primary exposure evaluated. Organization, where normal BMI is <25 kg/m2, overweight is 25.0-29.9 kg/m2, and obese is ≥30 kg/m2.
The primary outcomes assessed were recurrence-free survival and breast cancer-specific survival.
Recurrence-free survival (RFS) was defined as time from diagnosis to local or distant recurrence or death from any cause, whichever occurred first. Breast cancer-specific survival (BCSS) was defined as time from diagnosis to death due to breast cancer. Death due to breast cancer was defined as death occurring after recurrence of breast cancer. Follow-up time was calculated from the date of diagnosis to the date of death or recurrence, last known follow-up, or date of study truncation. Patients were censored at last follow-up if the event did not occur.
The demographic and clinical characteristics of patients with different breast cancer subtypes were examined using the χ2 test and ANOVA test for categorical and continuous variables, respectively.
We used multivariable-adjusted Cox proportional hazards models to evaluate the impact of BMI at diagnosis on RFS and BCSS across each subtype, reporting hazard ratios and 95% confidence intervals (CI). We excluded 338 patients with stage IV disease or missing stage data from the recurrence analysis.
All models were adjusted for age at diagnosis (5-year categories), race, stage, receipt of surgery (yes/no), receipt of chemotherapy (yes/no), receipt of radiation therapy (yes/no), receipt of hormonal treatment for luminal and H2E subtypes (yes/no), and receipt of Herceptin (yes/no) for H2E subtype.
Additional analyses stratified by menopausal status were conducted, excluding 7 women with unknown menopausal status, and menopausal status was evaluated as a potential effect modifier. Menopausal status was determined from medical records. Postmenopausal women included those who had natural menopause or induced menopause by bilateral oophorectomy and 338 Perimenopausal cases were included in the premenopausal group. Analyses were performed using Stata/SE (Stata Corp, College Station, TX).
RESULTS
Demographic and clinical characteristics by breast cancer subtype are summarized in Table 1 . were most likely to be obese.
Median follow-up was 7-years. At the time of this analysis, 571 (15%) women had experienced a recurrence and 709 (16%) of all women had died. Of all deaths, 465 (10% of total) occurred after cancer recurrence and were attributed to breast cancer. BMI was not associated with risks of recurrence or mortality among patients with luminal A or luminal B tumors. Menopausal status was not found to be a significant effect modifier of the association between BMI and recurrence or survival. Thus, stratified results are not presented.
DISCUSSION
Data from this large population-based study suggests that there is heterogeneity in the relationship between BMI and prognosis of breast cancer by molecular subtype. While previous studies indicate that obese breast cancer survivors have worse outcomes, our results suggest that obesity may contribute to an increased risks of recurrence and mortality only among women with H2E disease but not to risks of recurrence and mortality of either luminal or TN breast cancer.
Many studies have linked obesity to prognosis among women with breast cancer. In a cohort of 18,967 women treated for early-stage breast cancer in Denmark, obesity was found to be an independent prognostic factor for developing distant metastatic disease and death due to breast cancer. [19] [20] [21] [22] . Few studies have included a group of women with H2E disease [23] [24] [25] and, to a best of our knowledge, no study has reported an association between obesity and breast cancer prognosis specific to this subgroup. Consistent with these studies, our data supports a heterogeneous relationship between obesity and breast cancer prognosis by receptor subtype.
However, we found obesity to be linked to inferior outcomes only among the subset of patients with H2E disease and, conversely, that being overweight is linked to improved outcomes among with TN disease.
Several mechanisms have been postulated to explain the adverse effects of obesity on breast cancer incidence, recurrence, and survival. Increased production of estrogen in excess adipose tissue leading to increased estrogen levels, particularly among postmenopausal women, may contribute to this relationship. The relationship linking menopausal status and BMI with prognostic outcome among women with breast cancer is complex; however, there is a growing body of evidence suggesting that, contrary to the relationship seen in breast cancer incidence, the relationship between obesity and prognosis is independent of menopausal status
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. This is supported by our study. Non-hormonal pathways, such as obesity-related increased levels of insulin, insulin like growth factors, and proinflammatory mediators promoting tumor growth, are also though to contribute to this relationship.
It remains uncertain which specific factors may drive prognosis of particular breast cancer subtypes.
In considering the results of this study, it is important to recognize its limitations. First, we do not have data on several important factors, such as diet, physical activity, and BMI after diagnosis that may be correlated with both exposure and outcomes and could potentially affect their relationship.
Second, recall bias is a potential concern for most retrospective studies, but in this study BMI was obtained from medical records for the majority of participants. There is also the potential for misclassification bias. ER, PR, and HER2 information was abstracted from cancer registries, which gather information from various sources with likely variable practices. Nonetheless, any misclassification is likely non-differential and not related to the exposure of interest. Lastly, with respect to generalizability, our population was predominantly non-Hispanic. We included few African American women but did recruit a substantially larger number of Hispanic women than have been included in prior similar studies.
This study contributes to the evidence that the effect of obesity differs across the major breast cancer subtypes and adds to our understanding of the prognosis of clinically aggressive TN and H2E
subtypes. This data spawns new questions as to the mechanism(s) underlying worse breast ca outcomes among obese H2E patients, which could include inadequate dosing of chemo and/or targeted biologic therapies (trastuzumab, pertuzumab)
